From May , 2005 , to March , 2006 , 288 patients were assessed for eligibility , and 230 were randomly assigned to receive interferon beta and high-dose daclizumab ( n = 75 ) , interferon beta and low-dose daclizumab ( n = 78 ) , or interferon beta and placebo ( n = 77 ) .
